GlassScriptPhysician profile
Steven J Todd
NPI 1972604510
$2,353.75
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $173 · 2021: $556 · 2022: $817 · 2023: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.04 | 2020-2023 | Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $216.78 | 2021-2023 | |
| Daiichi Sankyo INC. | $179.20 | 2021-2023 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $178.08 | 2019-2023 | |
| Isoray, INC | $172.94 | 2020-2022 | |
| Amgen INC. | $118.16 | 2021-2022 | |
| Janssen Biotech, INC. | $110.19 | 2021-2023 | |
| Genzyme Corporation | $86.71 | 2019-2022 | |
| Tersera Therapeutics LLC | $83.53 | 2020-2023 | Zoladex |
| Merck Sharp & Dohme LLC | $72.19 | 2021-2023 | Welireg, Lynparza, Keytruda |
| Genentech USA, INC. | $70.51 | 2020-2023 | Tecentriq, Alecensa |
| Eisai INC. | $60.26 | 2022-2023 | |
| Lilly USA, LLC | $56.92 | 2019-2022 | |
| Abbvie INC. | $56.54 | 2021-2023 | Venclexta |
| Sobi, INC | $54.61 | 2022-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $49.67 | 2023 | Spaceoar Vue System - 10ml |
| Pfizer INC. | $47.96 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $44.66 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $44.10 | 2023 | Imbruvica |
| Seagen INC. | $33.05 | 2022-2023 | Adcetris |
| Incyte Corporation | $28.40 | 2021-2022 | |
| Blue Earth Diagnostics | $27.27 | 2021 | |
| Cti Biopharma Corp. | $22.78 | 2022 | |
| Servier Pharmaceuticals LLC | $22.33 | 2021 | |
| Novocure INC. | $21.71 | 2019 | |
| Palette Life Sciences, INC. | $21.18 | 2021 | |
| Eusa Pharma (US) LLC | $20.53 | 2020 | |
| Accuray Incorporated | $20.26 | 2019 | |
| Deciphera Pharmaceuticals INC. | $20.17 | 2023 | Qinlock |
| Adaptive Biotechnologies Corporation | $19.83 | 2022 | |
| Karyopharm Therapeutics INC. | $19.51 | 2023 | Xpovio |
| Varian Medical Systems, INC. | $19.15 | 2020 | |
| Glaxosmithkline, LLC. | $18.59 | 2021 | |
| Morphosys, US INC. | $18.27 | 2022 | |
| Emd Serono, INC. | $16.46 | 2023 | Bavencio |
| Astellas Pharma US INC | $14.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.